AU2003218870A1 - Treatment for diseases of the eye, inner ear and central nervous system - Google Patents

Treatment for diseases of the eye, inner ear and central nervous system

Info

Publication number
AU2003218870A1
AU2003218870A1 AU2003218870A AU2003218870A AU2003218870A1 AU 2003218870 A1 AU2003218870 A1 AU 2003218870A1 AU 2003218870 A AU2003218870 A AU 2003218870A AU 2003218870 A AU2003218870 A AU 2003218870A AU 2003218870 A1 AU2003218870 A1 AU 2003218870A1
Authority
AU
Australia
Prior art keywords
diseases
eye
treatment
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003218870A
Other languages
English (en)
Inventor
Ulrich Schraermeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cevec Pharmaceuticals GmbH
Original Assignee
Cevec Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals GmbH filed Critical Cevec Pharmaceuticals GmbH
Publication of AU2003218870A1 publication Critical patent/AU2003218870A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Eye Examination Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2003218870A 2002-02-18 2003-02-12 Treatment for diseases of the eye, inner ear and central nervous system Abandoned AU2003218870A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10206723.6 2002-02-18
DE10206723A DE10206723A1 (de) 2002-02-18 2002-02-18 Therapie von Erkrankungen des Auges und des Zentralen Nervensystems
PCT/DE2003/000415 WO2003070269A1 (de) 2002-02-18 2003-02-12 Therapie von erkrankungen des auges, des innenohres und des zentralen nervensystems

Publications (1)

Publication Number Publication Date
AU2003218870A1 true AU2003218870A1 (en) 2003-09-09

Family

ID=27674717

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003218870A Abandoned AU2003218870A1 (en) 2002-02-18 2003-02-12 Treatment for diseases of the eye, inner ear and central nervous system

Country Status (6)

Country Link
US (1) US7488749B2 (de)
EP (1) EP1478389B1 (de)
AT (1) ATE419864T1 (de)
AU (1) AU2003218870A1 (de)
DE (3) DE10206723A1 (de)
WO (1) WO2003070269A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
US20050226825A1 (en) * 2004-04-13 2005-10-13 Giampapa Vincent C Topical composition for preventing and treating skin damage caused by UV light exposure
US8568637B2 (en) 2004-08-02 2013-10-29 Ramot At Tel-Aviv University Ltd. Method of forming a fiber made of peptide nanostructures
WO2006018850A2 (en) 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
JP5079503B2 (ja) * 2005-06-07 2012-11-21 株式会社インバイオテックス ラジカルスカベンジャー及び活性酸素消去剤
WO2007013147A1 (ja) * 2005-07-27 2007-02-01 Inbiotex Inc. 血管新生阻害剤及び血管退縮剤
WO2007043048A2 (en) 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
CA2721360A1 (en) * 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting F Or And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
JP5815552B2 (ja) 2009-12-08 2015-11-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 眼疾患を治療する化合物および方法
KR20150047158A (ko) * 2013-10-24 2015-05-04 삼성전자주식회사 스트레스 관리 시스템 및 그 방법
EP3927330A4 (de) * 2019-02-19 2022-11-30 The Regents of the University of California Nurr1-rezeptormodulatoren

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01112483A (ja) * 1987-10-27 1989-05-01 Matsushita Electric Works Ltd 熱線式検知器
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5126125A (en) * 1989-10-06 1992-06-30 Yale University Decreasing the melanin content in mammalian skin and hair using 5,6-dihydroxindole derivatives
US5686084A (en) 1995-12-06 1997-11-11 Clairol Incorporated Synthesis of quaternary melanin compounds and their use as hair dyes or for skin treatment
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
CA2341903A1 (en) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
DE50213781D1 (de) 2001-02-21 2009-10-01 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung

Also Published As

Publication number Publication date
DE10390601D2 (de) 2005-01-27
ATE419864T1 (de) 2009-01-15
EP1478389B1 (de) 2009-01-07
US20050142128A1 (en) 2005-06-30
WO2003070269A1 (de) 2003-08-28
DE10206723A1 (de) 2003-09-04
EP1478389A1 (de) 2004-11-24
DE50311048D1 (de) 2009-02-26
US7488749B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
AU2003276028A1 (en) Pyridine derivatives as cb2 receptor modulators
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
AU2003218870A1 (en) Treatment for diseases of the eye, inner ear and central nervous system
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
WO2005013892A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
NO991732L (no) Nye heterocyklylmetylsubstituerte pyrazolderivater
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
RS20050104A (en) Indole or benzimidazole derivatives for modulating ikb kinase
NZ516347A (en) Indanyl-substituted benzenecarboxamides, process for their preparation, their use as a medicament and pharmaceutical formulations containing them
AU6050600A (en) Use of long-chain n-alkyl derivates of deoxynojirimycin and a glucocerebrosidaseenzyme for the manufacture of medicament for the treatment of glycolipid storag e diseases
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2003255819A1 (en) Pyrimidine derivatives as modulators of chemokine receptor activity
WO2005087210A3 (en) Prevention of retinopathy by inhibition of the visual cycle
AU3850600A (en) Dalda analogs and their use
AU2002352531A1 (en) Use of at least one glycoinhibitor substance
HUP0202745A2 (hu) Profilaktikus és terápiás szerek szembetegségek kezelésére
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
DE59904180D1 (de) Cyclopentabenzofuran-derivate und ihre verwendung
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
WO2002100836A8 (en) Compounds, compositions and methods for modulating beta-amyloid production
GR3025568T3 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase